IRVINE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN ® , today announced a strategic partnership for healthy aging research with the Jiangxi Provincial Government, People’s Republic of China.



Wu Zhongqiong, Vice Governor of the People’s Government of Jiangxi Province, commenced the ceremony at the Jiangxi Qianhu State Guesthouse on Thurs., Sept. 13. Additional presentations followed from Madame Wang of Qifeng Food Technology, Dr. Katherine Lo of the Li Ka Shing Foundation, Robert Fried of ChromaDex, and Drs. Charles Brenner and Roger Kornberg of the ChromaDex Scientific Advisory Board.

“We are grateful to have met with the leaders of the great province of Jiangxi and look forward to furthering this relationship,” says ChromaDex CEO Rob Fried. “This is an important first step in our long-term commitment to China.”

“This is a momentous occasion here in Jiangxi,” says Kornberg, who won the Nobel Prize in Chemistry in 2006. “I look forward to the research and progress in the study of aging that will come from this new initiative.”

"I’m thrilled to present the foundational science of nicotinamide riboside (NR) and the safe, evidence-based commercialization of our ingredient to Nanchang and Jiangxi Province,” says Brenner. “The global interest in our technology is exciting, and I look forward to advancing our research and development even further." Brenner discovered NR and is the Chief Scientific Advisor at ChromaDex.

The initiative will allow Jiangxi to become a foothold for advanced scientific research and business development to solve the problem of aging. The parties continue to discuss the details of the relationship, including their respective contributions to the venture, with the anticipation of finalizing definitive agreements later this year.

In addition to the anti-aging initiative, the ceremony also celebrated the launch of the Food Technology Science Park, in collaboration with Qifeng Food Technology Co. of Beijing, to build a world-class, tech-centric science research complex in Jiangxi.

For additional information on the science supporting TRU NIAGEN visit www.truniagen.com .

About TRU NIAGEN®:

TRU NIAGEN® is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex. NIAGEN® nicotinamide riboside (NR), also supplied by ChromaDex, is the sole active ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN® has twice been successfully reviewed under FDA's new dietary ingredient (“NDI”) notification program, and has also been successfully notified to the FDA as generally recognized as safe (“GRAS”).

About ChromaDex:

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN ® nicotinamide riboside, sold directly to consumers as TRU NIAGEN ® , is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN ® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. ChromaDex provided research materials and a portion of the grant funding as a collaborator for the study.

ChromaDex Media Contact:

Alex Worsham, Director of Strategic Partnerships

949-648-3775

alexw@chromadex.com

ChromaDex Investor Relations Contact:

Andrew Johnson, Director of Investor Relations

949-419-0288

andrewj@chromadex.com